21829-15-2

Upstream product

• 21881-54-9 2,6-dimethyl-4-(4-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester 
• 141-97-9 ethyl acetoacetate 
• 555-16-8 4-nitrobenzaldehdye 
• 7165-13-1 acetic butyric anhydride 

Downstream Products

• 1384460-67-6 diethyl 4-(4-(3-(2-chloro-5-(trifluoromethyl)phenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-68-7 diethyl 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-69-8 diethyl 4-(4-(3-(3,4-dichlorophenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-70-1 diethyl 4-(4-(3-(2,5-dichlorophenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-71-2 diethyl 4-(4-(3-(2,4-dichlorophenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-72-3 diethyl 2,6-dimethyl-4-(4-(3-(4-(trifluoromethyl) phenyl)ureido) phenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-73-4 diethyl 4-(4-(3-(4-chlorophenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-74-5 diethyl 4-(4-(3-(4-fluorophenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-75-6 diethyl 4-(4-(3-(4-cyanophenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1384460-76-7 diethyl 4-(4-(3-(2,5-difluorophenyl)ureido)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 

Relevant academic research and scientific papers

Design, synthesis, spectral characterization and molecular docking studies of novel pyranoquinolinyl dihydropyridine carboxylates as potential antibacterial agents including Vibrio cholerae with minimal cytotoxity towards fibroblast cell line (L-929)

Novel pyranoquinolinyl dihydropyridine carboxylate (PDC) derivatives were designed by incorporating the multi-drug resistance modulating effects of 1,4 dihydropyridines along with potential antibacterial activity of quinolines in the molecular design. The

The synthesis, anti-inflammatory, and anti-microbial activity evaluation of new series of 4-(3-arylureido)phenyl-1,4-dihydropyridine urea derivatives

A new series of 4-(3-arylureido)phenyl-1,4-dihydropyridine urea derivatives were synthesized using simple three component condensation, reduction, and nucleophilic addition sequence in moderate to good yields. All the synthesized compounds 6a-j were evaluated for their anti-inflammatory [against the pro-inflammatory cytokines (tumor necrosis factor-alpha, TNF-α and interleukin-6, IL-6)] and anti-microbial activity (anti-bacterial and anti-fungal). Among all the compound screened, the compound 6b, 6f, and 6j were found to have promising anti-inflammatory activity, 74-83 % TNF-α and 91-96 % IL-6 inhibitory activity, respectively as compared to the standard dexamethasone (71 and 86 % inhibition) but at the MIC of 10 μM/ml. The compounds 6d-e and 6h exhibited relatively lower TNF-α and IL-6 inhibitory activity and found to be moderately potent anti-inflammatory agents. The compounds 6c-e, 6g, and 6i were found to be promising anti-bacterial and anti-fungal agents and remarkably some of the new compounds, viz. 6d and 6i were found be more potent than the standard ciprofloxacin or miconazole. It is to be noted that this is the first report on the anti-inflammatory activity evaluation of novel 1,4-dihydropyridine urea derivatives against the important molecular target, TNF-α, and IL-6.

Synthesis and pharmacological evaluation of novel homocamptothecin- dihydropyridine derivative conjugates as potent topoisomerase i inhibitors

Homocamptothecins (hCPT) represent a new generation of antitumour agents targeting DNA topoisomerase I. The expanded seven-membered lactone E-ring that characterizes hCPT enhances the plasma stability of the drug and reinforces the inhibition of topoisomerase I (Topo I) compared with conventional six-membered CPT. In an attempt to improve the antitumour activity of hCP, a series of novel hCPT derivatives conjugating with dihydropyridine derivates were designed and synthesized based on a synthetic route that couples 7-formylhomocamptothecin with different dihydropyridine derivates. Most of the synthesized compounds exhibited good cytotoxic activity on tumour cell line A549, MDA-MB-435, and HCT116. Furthermore, this class of compounds showed superior Topo I inhibition activity comparable to or higher than CPT. CSIRO 2011.